at ASCO meeting heard Dr. Robert Carlson of Stanford

[Lani]

(usually one of the most conservative voices on many committees setting national standards) say that the next thing he sees is trials to determine which her2+ bc patients can be treated without chemo-- not just those best treated with herceptin+lapatinib or herceptin+pertuzumab, but also herceptin alone.

I always imagined he would be one of the last people I would hear this from having heard him speak at multiple meetings.

Here's to hoping for some day in the not too distant future when her2+ patients won't have to undergo nontargeted treatment

His comments were made during a panel discussion presented by ( andvideo'd) Dr. Neil Love's organization (had the word "controversies" in the title) so it should be available online sometime soon

Lots of discussion of adjuvant treatment and treatment of Stage IV her2+ breast cancer during the panel.